ProCE Banner Activity

CE / CME

Advances in Precision Cancer Care for Community Practitioners: A Focus on NTRK- and RET-Altered Malignancies

Multimedia
Watch this on-demand webcast of a live CCO webinar to gain expert insight on managing NTRK- and RET-altered malignancies, including optimal methods for detecting gene fusions.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.

Share

Faculty

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Thomas Stinchcombe

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Saad A. Khan

Saad A. Khan, MD

Leader, Endocrine Cancer Research Group
Assistant Professor
Stanford University and Stanford Cancer Institute
Stanford, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Lilly

Target Audience

This program is intended for community medical oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with NTRK- and RET-altered malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Order appropriate screening to detect NTRK and RET gene fusions
  • Describe the clinical research data supporting the use of TRK inhibition in NTRK fusion–positive and RET fusion–positive patients across all solid tumors
  • Summarize ongoing research regarding the efficacy and safety of selective RET inhibitors in patients with RET fusion–positive mutations across various tumor types
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK and RET inhibitor therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consultant/advisor/speaker fees from 14ner/Elevation Oncology, AbbVie, Amgen, Applied Pharmaceutical Science ArcherDX, AstraZeneca, AXIS, BeiGene, BergenBio, Blueprint Medicines, Chugai Pharm, EMD Serono, EPG Health, Entos, Exelixis, Harborside, Helsinn, Hengrui, Ignyta/Genentech/Roche, Janssen, Liberum, Loxo/Bayer/Lilly, mBrace, Medendi, Merus, Monopteros, MORE Health, Nexus, Novartis, Nuvalent, Ology, Pfizer, Prelude, Remedica, Repare RX, RV More, Takeda/Ariad/Millennium, TouchIME, TP Therapeutics, Treeline Bio, Tyra Biosciences, and Verastem and funds for research support (paid to institution) from Exelixis, GlaxoSmithKline, PharmaMar, Pfizer, Taiho, and Teva.

Thomas Stinchcombe, MD

Medical Oncologist
Thoracic Oncology Program
Duke University Medical Center
Durham, North Carolina

Thomas Stinchcombe, MD, has disclosed that he has received consultant/advisor/speaker fees from AstraZeneca, Daiichi Sankyo, EMD Serono, Foundation Medicine, Genentech/Roche, Janssen Oncology, Lilly, Medtronic, Novartis, Pfizer, Puma Biotechnology, Regeneron, Turning Point Therapeutics, Sanofi/Aventis, and Takeda and funds for research support paid to his institution from Advaxis, AstraZeneca, Genentech/Roche, Mirati, Regeneron, and Takeda.

Faculty Disclosure

Primary Author

Saad A. Khan, MD

Leader, Endocrine Cancer Research Group
Assistant Professor
Stanford University and Stanford Cancer Institute
Stanford, California

Saad A. Khan, MD, has disclosed that he has received consultant/advisor/speaker fees from Eisai and Foundation Medicine.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael Andrie, PhD, has no relevant conflicts of interest to report.

Nathan Beach, PhD

Editorial Contributor

Nathan Beach, PhD, has no relevant conflicts of interest to report.

Kelly Brandt, PharmD

Kelly Brandt, PharmD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, RN, MSN, RNP, AOCN, has disclosed that she has received speaker fees from AstraZeneca. Bristol-Myers Squibb, DSI, Gilead, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-153-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 10, 2022, through June 09, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with NTRK- and RET-altered malignancies.